Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
about
Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group
description
article
@en
im September 2018 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2018
@uk
name
Everolimus in patients with mu ...... Testicular Cancer Study Group
@en
Everolimus in patients with mu ...... Testicular Cancer Study Group
@nl
type
label
Everolimus in patients with mu ...... Testicular Cancer Study Group
@en
Everolimus in patients with mu ...... Testicular Cancer Study Group
@nl
prefLabel
Everolimus in patients with mu ...... Testicular Cancer Study Group
@en
Everolimus in patients with mu ...... Testicular Cancer Study Group
@nl
P2093
P50
P1476
Everolimus in patients with mu ...... Testicular Cancer Study Group
@en
P2093
Anja Lorch
Annette Dieing
Carsten Bokemeyer
Hans-Georg Kopp
Karin Oechsle
Marcus Hentrich
Thomas Gauler
P2888
P304
P356
10.1007/S00432-018-2752-Z
P577
2018-09-19T00:00:00Z